Primary Site >> Colorectal Cancer
Gene >> DPYD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. PMID: 8996166 |
Ref: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. PMID: 9472644 Ref: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. PMID: 9472650 Ref: Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. PMID: 9732227 Ref: Clinical development of eniluracil: current status. PMID: 9830627 Ref: Autoregulation of 5-fluorouracil metabolism. PMID: 9893640 Ref: Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. PMID: 9951876 |
Ref: Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. PMID: 10099659 Ref: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. PMID: 10213225 Ref: Fluoropyrimidines: a critical evaluation. PMID: 10436410 Ref: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. PMID: 10473078 Ref: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. PMID: 10499634 Ref: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. PMID: 10537350 Ref: [Dihydropyrimidine dehydrogenase gene expression in patients with hepatic metastases from colorectal cancer]. PMID: 10560382 Ref: Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. PMID: 10561307 Ref: Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. PMID: 10595802 Ref: Oral fluoropoyrimidines. PMID: 10606257 Ref: Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. PMID: 10632324 Ref: Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. PMID: 11810506 Ref: 5-Fluorouracil metabolizing enzymes. PMID: 21374032 |
Ref: Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. PMID: 10660460 Ref: New directions in the treatment of colorectal cancer: a look to the future. PMID: 10738119 Ref: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. PMID: 10755317 Ref: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. PMID: 10778957 Ref: Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. PMID: 10811492 Ref: Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. PMID: 10854135 Ref: [Metastatic colorectal cancer: new therapeutics]. PMID: 10874920 Ref: Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. PMID: 10901361 Ref: [Analysis of the salvage synthesis within biosynthesis of nucleic acid route in colon cancer]. PMID: 10969598 Ref: Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. PMID: 11060767 Ref: The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. PMID: 11081569 Ref: Pharmacology of fluorinated pyrimidines: eniluracil. PMID: 11081573 Ref: [Clinical significance of determinations of dihydropyrimidine dehydrogenase levels in primary and hepatic lesions of colorectal cancer patients]. PMID: 11086435 Ref: [Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer]. PMID: 11086436 Ref: Impact of UFT on tumoral TS and DPD levels in colorectal cancer. PMID: 11098489 |
Ref: Determinants of prognosis and response to therapy in colorectal cancer. PMID: 11177741 Ref: UFT in the treatment of colorectal and breast cancer. PMID: 11219978 Ref: Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. PMID: 11283924 Ref: Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. PMID: 11295091 Ref: Clinical relevance of the concentrations of both pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. PMID: 11302344 Ref: [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats]. PMID: 11383214 Ref: [Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydr PMID: 11383215 Ref: [Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]. PMID: 11432349 Ref: Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. PMID: 11445849 Ref: Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer. PMID: 11501504 Ref: Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. PMID: 11555593 Ref: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. PMID: 11555601 Ref: Serum factors attenuating the anti-tumor activity of 5-fluorouracil. PMID: 11603002 Ref: Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. PMID: 11668512 Ref: Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. PMID: 11697844 Ref: [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. PMID: 11707995 Ref: [Activities of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with colorectal cancer]. PMID: 11791381 |
Ref: Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. PMID: 11862480 Ref: [Correlation between clinical pathophysiologic factors and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer]. PMID: 11915731 Ref: Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. PMID: 11953843 Ref: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. PMID: 11956613 Ref: Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. PMID: 11962674 Ref: [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]. PMID: 11977552 Ref: Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. PMID: 12022983 Ref: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. PMID: 12084458 Ref: [Dihydropyrimidine dehydrogenase and thymidylate synthase in colon carcinoma]. PMID: 12090040 Ref: Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. PMID: 12095978 Ref: Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. PMID: 12352929 Ref: Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. PMID: 12406569 Ref: Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. PMID: 12410361 Ref: Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. PMID: 12448660 Ref: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. PMID: 12494248 |
Ref: Differential effects of two fluorouracil administration regimens for colorectal cancer. PMID: 12469154 Ref: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. PMID: 12576451 Ref: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. PMID: 12576452 Ref: Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens. PMID: 12647017 Ref: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. PMID: 12720098 Ref: [Thymidine phosphorylase is correlated with DPD in colon cancer]. PMID: 12722680 Ref: The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection. PMID: 12792736 Ref: Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody. PMID: 12820455 Ref: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. PMID: 12841874 Ref: The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy. PMID: 12845947 Ref: Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. PMID: 12866042 Ref: Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer. PMID: 12870370 Ref: Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival. PMID: 12883718 Ref: Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. PMID: 12904894 Ref: Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens. PMID: 12960741 Ref: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. PMID: 14519634 Ref: Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. PMID: 14551502 Ref: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. PMID: 14562021 Ref: [Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases]. PMID: 14574888 Ref: Study of in vitro and in vivo effects of 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells. PMID: 14612915 Ref: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. PMID: 14612954 |
Ref: Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. PMID: 14744539 Ref: Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer. PMID: 14992436 Ref: Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer. PMID: 15015608 Ref: Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. PMID: 15017333 Ref: Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. PMID: 15025795 Ref: Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. PMID: 15060742 Ref: Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. PMID: 15069545 Ref: Preoperative endoscopic analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in gastrointestinal cancer. PMID: 15138561 Ref: [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. PMID: 15222105 Ref: [Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method]. PMID: 15222106 Ref: [Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues]. PMID: 15272584 Ref: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. PMID: 15309506 Ref: The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. PMID: 15363468 Ref: [Prognosis and efficacy of postoperative adjuvant chemotherapy in colorectal cancer correlates with nucleic acid metabolizing enzymes]. PMID: 15446556 Ref: Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. PMID: 15538739 Ref: [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients]. PMID: 15566669 Ref: Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. PMID: 15688605 |
Ref: Effects of 1, 6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a reactive oxygen species and apoptosis inducing agent, on human leukemia cells in vitro and in vivo. PMID: 15589971 Ref: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. PMID: 15655543 Ref: [Assessment of dihydropyrimidine dehydrogenase and thymidylate synthase expression in gastric carcinoma and colonic carcinoma]. PMID: 15751630 Ref: Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer. PMID: 15770397 Ref: Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. PMID: 15814641 Ref: [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. PMID: 15820075 Ref: Changes over time in thymidine phosphorylase and dihydropyrimidine dehydrogenase when colon cancer samples are left at room temperature. PMID: 15837547 Ref: Expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53 and p21 in metastatic liver tumor from colorectal cancer after 5-fluorouracil-based chemotherapy. PMID: 15865071 Ref: Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue. PMID: 15875081 Ref: Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil. PMID: 15911984 Ref: [Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance]. PMID: 15968317 Ref: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. PMID: 16012177 Ref: The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken. PMID: 16012711 Ref: Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. PMID: 16147904 Ref: Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemorad PMID: 16160472 Ref: [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment]. PMID: 16282729 Ref: Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. PMID: 16302736 Ref: [Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications]. PMID: 16313827 Ref: [Clinicopathological significance of pyrimidine nucleoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in advanced colorectal cancer]. PMID: 16315907 Ref: Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. PMID: 16334763 Ref: Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. PMID: 17375478 |
Ref: Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. PMID: 16132996 Ref: Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. PMID: 16251201 Ref: Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C. PMID: 16353181 Ref: Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. PMID: 16362295 Ref: Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype. PMID: 16387426 Ref: Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. PMID: 16391809 Ref: Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. PMID: 16425285 Ref: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. PMID: 16477629 Ref: Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. PMID: 16525674 Ref: Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma. PMID: 16554992 Ref: Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. PMID: 16568373 Ref: 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. PMID: 16572420 Ref: Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. PMID: 16619549 Ref: Individualizing chemotherapeutic treatment of colorectal cancer. PMID: 16641252 Ref: Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. PMID: 16761622 Ref: [Correlation between clinical pathologic factors and enzymatic activity of orotate Phosphoribosyl transferase (OPRT), Dihydropyrimidine dehydrogenase (DPD) and Thymidylate synthase (TS) in colorectal cancer]. PMID: 16770098 Ref: The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer. PMID: 16786143 Ref: Methylenetetrahydrofolate reductase C677T is not associated with expression of pyrimidine metabolic enzyme genes in colorectal cancer. PMID: 16866026 Ref: Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. PMID: 16931962 Ref: Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. PMID: 16943523 Ref: Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. PMID: 17000684 Ref: Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. PMID: 17026792 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. PMID: 17047489 Ref: The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance. PMID: 17089033 Ref: [Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer]. PMID: 17108726 Ref: Pharmacogenomics and colorectal cancer. PMID: 17163168 Ref: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. PMID: 17179731 Ref: Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. PMID: 17241513 |
Ref: Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. PMID: 17046731 Ref: The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. PMID: 17096352 Ref: Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. PMID: 17203168 Ref: [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report]. PMID: 17220684 Ref: The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. PMID: 17308379 Ref: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. PMID: 17330233 Ref: Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. PMID: 17349846 Ref: Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. PMID: 17417073 Ref: Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. PMID: 17454858 Ref: Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. PMID: 17465211 Ref: Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees. PMID: 17551252 Ref: DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. PMID: 17611699 Ref: Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. PMID: 17612628 Ref: Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. PMID: 17629045 Ref: [Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer]. PMID: 17637543 Ref: [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. PMID: 17660867 Ref: Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. PMID: 17688376 Ref: Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. PMID: 17699798 Ref: DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. PMID: 17848752 Ref: Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. PMID: 17952005 Ref: Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. PMID: 18225548 |
Ref: Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. PMID: 17520254 Ref: Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. PMID: 17637782 Ref: The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. PMID: 17700593 Ref: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. PMID: 18245778 Ref: Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. PMID: 18288408 Ref: High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. PMID: 18309485 Ref: Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. PMID: 18360075 Ref: 5-Fluorouracil-related gene expression in hepatic artery infusion-treated patients with hepatic metastases from colorectal carcinomas. PMID: 18383874 Ref: 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. PMID: 18443386 Ref: A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. PMID: 18473752 Ref: [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase]. PMID: 18597209 Ref: Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy. PMID: 18597678 Ref: Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors. PMID: 18613375 Ref: DNA methylotype analysis in colorectal cancer. PMID: 18813836 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. PMID: 19020767 Ref: Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? PMID: 19037763 Ref: Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PMID: 19104657 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. PMID: 19105824 |
Ref: The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. PMID: 18619742 Ref: A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. PMID: 18803264 Ref: Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. PMID: 19051292 Ref: Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. PMID: 19052026 Ref: Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. PMID: 19154585 Ref: Dihydropyrimidine dehydrogenase mRNA expression in peripheral blood of rectal cancer patients is significantly associated with residual tumor and distant metastases following resection. PMID: 19180589 Ref: Pharmacogenetics in chemotherapy of colorectal cancer. PMID: 19414151 Ref: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. PMID: 19457654 Ref: Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. PMID: 19473056 Ref: High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. PMID: 19491899 Ref: Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues. PMID: 19724871 Ref: Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? PMID: 19822515 Ref: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. PMID: 19858398 Ref: [Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil]. PMID: 20037380 |
Ref: Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase. PMID: 19830428 Ref: Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. PMID: 19877119 Ref: [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. PMID: 20219304 Ref: Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer. PMID: 20407238 Ref: Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV. PMID: 20500514 Ref: [Recent developments of pharmacogenomics in the treatment of colorectal cancers]. PMID: 20637356 Ref: Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. PMID: 20653680 Ref: Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. PMID: 20665215 Ref: Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. PMID: 20819423 Ref: Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? PMID: 20920994 Ref: The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. PMID: 20926004 Ref: [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems]. PMID: 21163769 Ref: Where should the specimen be excised for the chemosensitivity of colorectal cancer to 5-fluorouracil? PMID: 21410037 |
Ref: Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability. PMID: 20387074 Ref: Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites. PMID: 21210725 Ref: A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. PMID: 21325291 Ref: [Investigation of chemotherapy based on enzyme expression and drug sensitivity test in colorectal cancer]. PMID: 21368461 Ref: Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. PMID: 21410976 Ref: Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. PMID: 21498394 Ref: Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. PMID: 21787270 Ref: Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. PMID: 21868518 Ref: The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. PMID: 21919605 Ref: Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. PMID: 21931273 Ref: Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. PMID: 22045187 Ref: [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. PMID: 22202337 |
Ref: X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. PMID: 21167658 Ref: Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. PMID: 21893437 Ref: TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. PMID: 22006578 Ref: Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. PMID: 22020693 Ref: ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. PMID: 22567180 Ref: Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. PMID: 22593457 Ref: Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. PMID: 22610353 Ref: Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis. PMID: 22641663 Ref: Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. PMID: 22783377 Ref: Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. PMID: 22909207 Ref: Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? PMID: 22911546 Ref: Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. PMID: 22978343 Ref: Splice isoforms as therapeutic targets for colorectal cancer. PMID: 23118106 Ref: High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. PMID: 23335937 Ref: Capecitabine Therapy and DPYD Genotype PMID: 28520372 Ref: Fluorouracil Therapy and DPYD Genotype PMID: 28520376 |
Ref: LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. PMID: 22454320 Ref: Analysis of the mRNA expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyl transferase (OPRT) in liver metastases from colorectal cancer. PMID: 22945388 Ref: Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. PMID: 23102544 Ref: Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. PMID: 23197286 Ref: Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study) PMID: 23232805 Ref: Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. PMID: 23328581 Ref: Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. PMID: 23332421 Ref: Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. PMID: 23575271 Ref: Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method. PMID: 23577026 Ref: DMET (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. PMID: 23760813 Ref: Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. PMID: 23781135 Ref: Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. PMID: 23812226 Ref: A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. PMID: 23836081 Ref: Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. PMID: 23942539 Ref: Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers. PMID: 24100378 Ref: Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PMID: 24167597 Ref: [A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer]. PMID: 24231713 Ref: Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. PMID: 24649191 |
Ref: Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. PMID: 24275137 Ref: Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. PMID: 24590654 Ref: Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. PMID: 24800948 Ref: The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: PMID: 24817302 Ref: Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. PMID: 24994673 Ref: Delayed Presentation of DPD Deficiency in Colorectal Cancer. PMID: 25089219 Ref: Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. PMID: 25102934 Ref: [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. PMID: 25137161 Ref: Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. PMID: 25202077 Ref: DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). PMID: 25381393 Ref: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). PMID: 25421252 Ref: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. PMID: 25614737 Ref: Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. PMID: 25664120 |
Ref: Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report. PMID: 24434920 Ref: A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. PMID: 24647007 Ref: Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity? PMID: 25301403 Ref: Frequent intragenic rearrangements of DPYD in colorectal tumours. PMID: 25348620 Ref: Prognostic value of biomarkers in metastatic colorectal cancer patients. PMID: 25456112 Ref: Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. PMID: 25677447 Ref: [Establishment and biological characterization of 5-fluorouracil-resistant human colon cancer HT-29/5-FU cell line]. PMID: 25744837 Ref: DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. PMID: 25782327 Ref: Costs and effectiveness of genomic testing in the management of colorectal cancer. PMID: 25783977 Ref: Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context. PMID: 25804843 Ref: MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. PMID: 25873402 Ref: Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. PMID: 25906475 Ref: Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. PMID: 25957957 Ref: Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. PMID: 26242620 Ref: Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. PMID: 26372896 Ref: The role of Reg IV in colorectal cancer, as a potential therapeutic target. PMID: 26557771 Ref: Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. PMID: 26722420 |
Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. PMID: 26676887 Ref: TAS-102 an Emerging Oral Fluoropyrimidine. PMID: 26722024 Ref: DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. PMID: 26794347 Ref: Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. PMID: 26967565 Ref: 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl] diamantane potentiates in vitro and in vivo antitumor effects of irinotecan on human colorectal cancer cells. PMID: 27123150 Ref: Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer. PMID: 27127154 Ref: DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients. PMID: 27461651 Ref: Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients. PMID: 27636992 Ref: Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma. PMID: 27733154 Ref: The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes. PMID: 27752409 Ref: Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. PMID: 27837635 |
Ref: 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. PMID: 27845948 Ref: A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. PMID: 28296649 Ref: Identification of new SNPs associated with severe toxicity to capecitabine. PMID: 28347776 Ref: Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. PMID: 28395758 Ref: Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. PMID: 28412781 Ref: Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine i PMID: 28501750 Ref: Low Incidence of the DPD IVS14+1G>A Polymorphism in Jordanian Breast and Colorectal Cancer patients PMID: 28670884 Ref: Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. PMID: 29065426 Ref: DPYD genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from Slovakia. PMID: 29372689 Ref: [Severe Therapy-Related Pancytopenia Caused by UFT and LV in a Patient with Ascending Colon Cancer]. PMID: 29394647 |
Ref: DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. PMID: 29134491 Ref: Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. PMID: 29596542 Ref: The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. PMID: 29681787 Ref: Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients. PMID: 29799355 Ref: The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer. PMID: 29845393 Ref: TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A gene mutation in Mexican colorectal cancer patients. PMID: 29906295 Ref: Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. PMID: 30075835 Ref: A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening. PMID: 30087856 Ref: Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. PMID: 30114658 Ref: Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. PMID: 30207288 Ref: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience. PMID: 30288154 Ref: The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice. PMID: 30339275 |